Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in P...
Q1 2026
May 11, 2026
FY 2025
Mar 12, 2026
Q4 2025
Q3 2025
Nov 13, 2025
Q2 2025
Aug 7, 2025